Alaska Permanent Fund Corp Buys 481 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Alaska Permanent Fund Corp boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,801 shares of the specialty pharmaceutical company’s stock after purchasing an additional 481 shares during the period. Alaska Permanent Fund Corp’s holdings in Jazz Pharmaceuticals were worth $2,313,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Covestor Ltd raised its holdings in Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after buying an additional 345 shares during the last quarter. Spire Wealth Management increased its holdings in Jazz Pharmaceuticals by 128.6% in the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 238 shares during the period. Headinvest LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth $56,000. Signaturefd LLC lifted its holdings in Jazz Pharmaceuticals by 85.7% during the 3rd quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 252 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $78,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CFO Philip L. Johnson purchased 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Corporate insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $0.25 during mid-day trading on Thursday, reaching $108.07. 39,866 shares of the company’s stock were exchanged, compared to its average volume of 601,060. The firm has a 50-day moving average price of $118.98 and a two-hundred day moving average price of $122.04. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The firm has a market capitalization of $6.81 billion, a price-to-earnings ratio of 17.70, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. Jazz Pharmaceuticals plc has a 52 week low of $106.61 and a 52 week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Analysts predict that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent analyst reports. Stifel Nicolaus increased their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. HC Wainwright decreased their price target on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, March 22nd. Finally, Robert W. Baird began coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 target price for the company. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.